Investigating how aging affects a specific microRNA linked to heart disease
8OH-G miR-483 contributes to the aging-accelerated atherosclerosis
This study is looking at how a tiny molecule called miR-483 affects the hardening of arteries as we age, especially when our bodies experience stress from things like pollution or unhealthy diets, and it hopes to find new ways to help keep our blood vessels healthy and prevent heart problems.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10793303 on NIH RePORTER |
What this research studies
This research explores the role of a microRNA called miR-483 in the development of atherosclerosis, particularly as it relates to aging. The study focuses on how oxidative stress can modify this microRNA, leading to changes in endothelial cell function, which is crucial for maintaining healthy blood vessels. By examining the relationship between aging, oxidative stress, and microRNA alterations, the research aims to uncover new mechanisms that contribute to cardiovascular diseases. Patients may benefit from insights that could lead to novel therapeutic strategies targeting these molecular changes.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults who are at risk for cardiovascular diseases, particularly those with signs of atherosclerosis.
Not a fit: Patients who are younger and do not have any cardiovascular risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent atherosclerosis in aging patients.
How similar studies have performed: Other research has shown promising results in understanding the role of microRNAs in cardiovascular diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: He, Ming — University of Alabama at Birmingham
- Study coordinator: He, Ming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.